Search results
PROMOTED
Start date:
Jan 21, 2026
Pacemaker implantation remains one of the most common complications after TAVI. In this webinar, chaired by Prof Rafal Dworakowski (Abbott APAC Medical Affairs Director, Singapore, SG) and Dr Simon Lam (Queen Mary Hospital, Hong Kong, HK), leading specialists will focus on the anatomy of the conduction system anatomy, highlight key pre-procedural planning considerations, and share proven…
View more
Added:
1 week ago
EuroPCR 2026 – Prof Georg Nickenig (University Hospital Bonn, DE) joins us to discuss interim results from the TARGET study, evaluating the safety and performance of the Cardiovalve TR transcatheter tricuspid valve replacement system in patients with symptomatic tricuspid regurgitation.The TARGET study is a multicentre, prospective, single-arm trial enrolling up to 100 patients across seven sites…
View more
Added:
1 year ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical…
View more
Added:
7 months ago
Dr Matthias Götberg (Skane University Hospital, SE), Dr Karim Al-Azizi (Baylor Scott & White Legacy Heart Center, US) and Prof Farrel Hellig (Sunninghill Hospital, ZA) delve into the evolving field of ultra-low contrast PCI. The faculty explore how interventional cardiologists can achieve procedural precision while significantly reducing contrast usage.Through a combination of expert…
View more
Start date:
Oct 30, 2025
Join Dr Matthias Götberg (Skane University Hospital, SE), Dr Karim Al-Azizi (Baylor Scott & White Legacy Heart Center, US) and Prof Farrel Hellig (Sunninghill Hospital, ZA) in this webinar as they delve into the evolving field of ultra-low contrast PCI. The faculty will explore how interventional cardiologists can achieve procedural precision while significantly reducing contrast usage.Through a…
View more
Added:
1 year ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Added:
11 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings…
View more
Added:
2 months ago
In this chapter of ICE and TEE Guidance for TriClip Tricuspid TEER, Dr Karim Al-Azizi (Baylor Scott & White Health – The Heart Hospital, US) demonstrates the step-by-step technical approach to TriClip tricuspid transcatheter edge‑to‑edge repair (TEER) using a dual‑imaging strategy.The case highlights vascular access techniques, device positioning, and the pivotal role of hybrid transoesophageal…
View more
Added:
7 months ago
TCT 2025 - Sub-anlysis findings showed positive safety and efficacy outcomes of the PASCAL Precision system in degenerative mitral regurgitation (DMR) patients.Dr P. Kasi Ramanathan (Promedica Toledo Hospital, OH, US) joins us on-site at TCT 2025 to share the findings from a sub-analysis looking at the affect of implant location and leaflet lesion location on the safety and effectiveness of the…
View more
Added:
3 months ago
Source:
Transcatheter Academy
Seven-year follow-up data from the PARTNER 3 trial shows no significant difference in key outcomes between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This long-term assessment provides further insight into valve durability and clinical outcomes, building on previous 5-year data which…
View more